Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Current Leases (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Current Leases readings, the most recent being $564000.0 for Q4 2024.

  • On a quarterly basis, Current Leases rose 72.48% to $564000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $564000.0, a 72.48% increase, with the full-year FY2024 number at $564000.0, up 72.48% from a year prior.
  • Current Leases hit $564000.0 in Q4 2024 for Unicycive Therapeutics, up from $542000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $564000.0 in Q4 2024 to a low of $151000.0 in Q4 2021.
  • Median Current Leases over the past 4 years was $303000.0 (2023), compared with a mean of $293461.5.
  • Biggest five-year swings in Current Leases: increased 2.65% in 2022 and later soared 110.97% in 2023.
  • Unicycive Therapeutics' Current Leases stood at $151000.0 in 2021, then grew by 2.65% to $155000.0 in 2022, then soared by 110.97% to $327000.0 in 2023, then skyrocketed by 72.48% to $564000.0 in 2024.
  • The last three reported values for Current Leases were $564000.0 (Q4 2024), $542000.0 (Q3 2024), and $360000.0 (Q2 2024) per Business Quant data.